|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
| (51) | INT.CL. | C07D 471/14 | (2006.01) |
| A61P 3/00 | (2018.01) | ||
| A61P 3/00 | (2006.01) | ||
| C07D 471/14 | (2013.01) | ||
| A61K 31/4375 | (2006.01) |
| (11) | Patento numeris | 3500570 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 17762266.9 |
| Europos patento paraiškos padavimo data | 2017-08-18 | |
| (97) | Europos patento paraiškos paskelbimo data | 2019-06-26 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2022-10-05 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (86) | Numeris | PCT/US2017/047644 |
| Data | 2017-08-18 |
| (87) | Numeris | WO 2018/035477 |
| Data | 2018-02-22 |
| (30) | Numeris | Data | Šalis |
| 201662377119 P | 2016-08-19 | US |
| (72) |
SEMPLE, Graeme , US
REN, Albert S. , US
SCHRADER, Thomas O. , US
KASEM, Michelle , US
ZHU, Xiuwen , US
|
| (73) |
Arena Pharmaceuticals, Inc. ,
235 East 42nd Street, New York, NY 10017,
US
|
| (54) | 5-HT2C RECEPTOR AGONISTS AND COMPOSITIONS AND METHODS OF USE |
| 5-HT2C RECEPTOR AGONISTS AND COMPOSITIONS AND METHODS OF USE |